OpenLB
Open Library of Bioscience
Advanced Search
Annals of medicine and surgery (2012)
Nov, 2024;86 (11): 6602-6618.

Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023.

Abinash Mahapatro, Ali Bozorgi, Sri U J Obulareddy, Shika M Jain, Rohan Reddy Korsapati, Aroon Kumar, Kristina Patel, Saman Soltani Moghadam, Arash Arya, Abdulhadi Jameel Alotaibi, Mohammad-Hossein Keivanlou, Soheil Hassanipour, Maryam Hasanpour, Ehsan Amini-Salehi
Author Information
  1. Abinash Mahapatro: Hi-Tech Medical College and Hospital, Rourkela, Odisha, India.
  2. Ali Bozorgi: Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.
  3. Sri U J Obulareddy: University of Arkansas, Little Rock, Arkansas, USA.
  4. Shika M Jain: MVJ Medical College and Research Hospital, Bengaluru, India.
  5. Rohan Reddy Korsapati: University of Toledo, Toledo, Ohio, USA.
  6. Aroon Kumar: Baylor College of Medicine, Houston, USA.
  7. Kristina Patel: Shenyang North New Area, Shenyang, Liaoning Province, People's Republic of China.
  8. Saman Soltani Moghadam: Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
  9. Arash Arya: Department of Internal Medicine III, Halle University Hospital, Halle (Saale), Germany.
  10. Abdulhadi Jameel Alotaibi: Vision Colleges, Riyadh, Saudi Arabia.
  11. Mohammad-Hossein Keivanlou: Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
  12. Soheil Hassanipour: Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
  13. Maryam Hasanpour: Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
  14. Ehsan Amini-Salehi: Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
PMID: 39525800 DOI: 10.1097/MS9.0000000000002592

Abstract

Background: In recent years, glucagon-like peptide-1 (GLP-1) agonists have garnered increasing attention for their potential cardiovascular benefits beyond glycemic control in patients with diabetes. Understanding the research landscape surrounding GLP-1 agonists and cardiovascular diseases (CVDs) is crucial for informing clinical practice and guiding future research endeavors. This bibliometric analysis aimed to comprehensively assess the scholarly output and trends in this field, shedding light on the evolving landscape of GLP-1 agonists' role in cardiovascular health.
Methods: The publications concerning GLP-1 agonists in CVDs were gathered from the Web of Science Core Collection, and visualizations were created utilizing Excel 2019, Cite Space, and VOS viewer software.
Results and Conclusion: Using bibliometric and visual methods, the research hotspots and trends regarding GLP-1 agonists in cardiovascular diseases were pinpointed. Additionally, a thriving interest in GLP-1 agonists research within cardiovascular medicine was observed, with a notable surge in publications from 2016 onwards. The analysis revealed that the United States and China are the leading contributors, accounting for over 50% of the total publications. The University of Copenhagen and the University of Toronto emerged as the most prolific institutions in this field. Co-citation analysis highlighted the influential role of landmark clinical trials, such as the LEADER, ELIXA, and EXSCEL. Keyword trend analysis identified the emergence of newer GLP-1 agonists, such as tirzepatide and semaglutide, as well as a growing focus on topics like 'healthy obesity' and chronic kidney disease. These findings suggest that the research landscape is evolving, with a focus on expanding the therapeutic applications of GLP-1 agonists beyond glycemic control. Overall, this bibliometric analysis provided insights into the current state and future directions of research on GLP-1 agonists and their impact on cardiovascular health, guiding future research endeavors, and informing clinical practice.

Keywords

bibliometric analysis cardiovascular diseases diabetes mellitus glucagon-like peptide-1 trend

References

  1. Ethiop J Health Sci. 2018 Nov;28(6):691-700 [PMID: 30607085]
  2. Nutr Metab Cardiovasc Dis. 2024 Sep;34(9):2046-2054 [PMID: 38902190]
  3. N Engl J Med. 2016 Nov 10;375(19):1834-1844 [PMID: 27633186]
  4. Arterioscler Thromb Vasc Biol. 2016 Oct;36(10):2125-32 [PMID: 27562916]
  5. Lancet Diabetes Endocrinol. 2021 Jan;9(1):46-52 [PMID: 33159841]
  6. N Engl J Med. 2015 Dec 3;373(23):2247-57 [PMID: 26630143]
  7. Postgrad Med. 2015;127(8):818-26 [PMID: 26371721]
  8. J Health Care Poor Underserved. 2011;22(4 Suppl):61-72 [PMID: 22102306]
  9. Kidney Res Clin Pract. 2022 Mar;41(2):136-149 [PMID: 35391537]
  10. Heart Lung. 2023 Jul-Aug;60:154-155 [PMID: 36878810]
  11. Lancet. 2023 Aug 19;402(10402):613-626 [PMID: 37385275]
  12. Nat Rev Cardiol. 2023 Jul;20(7):463-474 [PMID: 36977782]
  13. J Int Med Res. 2023 Mar;51(3):3000605231164548 [PMID: 36994866]
  14. Int J Mol Sci. 2023 Jun 21;24(13): [PMID: 37445623]
  15. J Innov Card Rhythm Manag. 2023 Jul 15;14(7):5514-5527 [PMID: 37492695]
  16. AMIA Annu Symp Proc. 2005;:724-8 [PMID: 16779135]
  17. Lancet. 2009 Feb 7;373(9662):473-81 [PMID: 18819705]
  18. Int J Mol Sci. 2023 Jan 15;24(2): [PMID: 36675217]
  19. Cureus. 2023 Oct 5;15(10):e46510 [PMID: 37808605]
  20. Diabetes Care. 2011 Jan;34(1):90-5 [PMID: 20929995]
  21. Diabetes Spectr. 2017 Aug;30(3):202-210 [PMID: 28848315]
  22. Lancet Diabetes Endocrinol. 2018 Nov;6(11):859-869 [PMID: 30292589]
  23. Diabetologia. 2009 Oct;52(10):2046-55 [PMID: 19688338]
  24. Front Endocrinol (Lausanne). 2022 Dec 09;13:1079725 [PMID: 36568108]
  25. N Engl J Med. 2010 Jul 15;363(3):233-44 [PMID: 20587587]
  26. Front Cardiovasc Med. 2021 Aug 25;8:734514 [PMID: 34513962]
  27. Curr Probl Cardiol. 2022 Nov;47(11):101332 [PMID: 35870550]
  28. Cardiovasc Diabetol. 2014 Oct 22;13:142 [PMID: 25338737]
  29. Eur J Intern Med. 2023 Jul;113:1-5 [PMID: 37183081]
  30. Nutr Diabetes. 2024 May 10;14(1):25 [PMID: 38729941]
  31. Front Immunol. 2022 Oct 21;13:1025861 [PMID: 36341351]
  32. Circulation. 2022 Dec 13;146(24):1882-1894 [PMID: 36508493]
  33. Cardiovasc Diabetol. 2023 Mar 17;22(1):60 [PMID: 36932379]
  34. Cureus. 2023 Sep 18;15(9):e45487 [PMID: 37859909]
  35. N Engl J Med. 2013 Oct 3;369(14):1317-26 [PMID: 23992601]
  36. JAMA. 2016 Aug 2;316(5):500-8 [PMID: 27483064]
  37. J Clin Endocrinol Metab. 2011 May;96(5):1301-10 [PMID: 21307137]
  38. Diabet Med. 2009 Mar;26(3):268-78 [PMID: 19317822]
  39. N Engl J Med. 2017 Aug 17;377(7):644-657 [PMID: 28605608]
  40. Cureus. 2022 Apr 3;14(4):e23784 [PMID: 35518523]
  41. Heart Lung. 2023 Jul-Aug;60:146-147 [PMID: 36914550]
  42. J Am Pharm Assoc (2003). 2024 Jan-Feb;64(1):133-138 [PMID: 37821008]
  43. Cardiovasc Diabetol. 2023 Mar 25;22(1):69 [PMID: 36966321]
  44. Heliyon. 2023 Jun 02;9(6):e16839 [PMID: 37346333]
  45. J Clin Med. 2020 Mar 30;9(4): [PMID: 32235471]
  46. Circulation. 2023 Feb 21;147(8):e93-e621 [PMID: 36695182]
  47. Cell Metab. 2018 Apr 3;27(4):740-756 [PMID: 29617641]
  48. Diabetes Obes Metab. 2013 Mar;15(3):204-12 [PMID: 22985213]
  49. Postgrad Med J. 2020 Mar;96(1133):156-161 [PMID: 31801807]
  50. PLoS One. 2012;7(12):e50117 [PMID: 23236362]
  51. Scientometrics. 2010 Aug;84(2):523-538 [PMID: 20585380]
  52. Arch Med Res. 2024 Sep;55(6):103043 [PMID: 39094335]
  53. Am Heart J. 2018 Sep;203:30-38 [PMID: 30015066]
  54. Am J Prev Cardiol. 2023 May 24;14:100502 [PMID: 37313358]
  55. Nat Med. 2022 Oct;28(10):2083-2091 [PMID: 36216945]
  56. Int J Mol Sci. 2022 Oct 26;23(21): [PMID: 36361701]
  57. Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113 [PMID: 29221659]
  58. Front Neurosci. 2021 Jan 20;14:620555 [PMID: 33551731]
  59. Metabolites. 2021 Jan 27;11(2): [PMID: 33513761]
  60. Cureus. 2023 Aug 21;15(8):e43882 [PMID: 37746454]
  61. Front Oncol. 2021 Feb 12;10:627891 [PMID: 33643922]
  62. N Engl J Med. 2017 Aug 31;377(9):839-848 [PMID: 28854085]
  63. Cardiovasc Diabetol. 2018 Jun 8;17(1):83 [PMID: 29884191]
  64. Front Cell Dev Biol. 2021 Oct 13;9:768689 [PMID: 34722552]
  65. Lancet. 2019 Jul 13;394(10193):121-130 [PMID: 31189511]
  66. N Engl J Med. 2010 Apr 22;362(16):1477-90 [PMID: 20228403]
  67. World J Nephrol. 2014 Nov 6;3(4):156-68 [PMID: 25374809]
  68. Lancet. 2008 Oct 4;372(9645):1240-50 [PMID: 18782641]
  69. Curr Probl Cardiol. 2023 Aug;48(8):101194 [PMID: 35395332]
  70. Lancet. 2009 Jul 4;374(9683):39-47 [PMID: 19515413]
  71. N Engl J Med. 2016 Jul 28;375(4):311-22 [PMID: 27295427]
  72. Int J Biol Sci. 2018 Sep 7;14(12):1696-1708 [PMID: 30416384]
  73. Syst Rev. 2023 Aug 21;12(1):144 [PMID: 37605283]
  74. Cardiovasc Res. 2020 Apr 1;116(5):916-930 [PMID: 31825468]
  75. Cureus. 2024 Mar 30;16(3):e57241 [PMID: 38686257]
  76. Curr Probl Cardiol. 2023 Nov;48(11):101892 [PMID: 37394201]
  77. BMC Med. 2024 Jan 4;22(1):8 [PMID: 38172833]
  78. Cureus. 2023 Apr 27;15(4):e38215 [PMID: 37252538]
  79. Kidney Int. 2014 Oct;86(4):701-11 [PMID: 25007170]
  80. N Engl J Med. 2017 Sep 28;377(13):1228-1239 [PMID: 28910237]
  81. Endocrine. 2017 Jan;55(1):66-76 [PMID: 27477292]
  82. Diabetologia. 2024 Mar;67(3):483-493 [PMID: 38117293]
  83. Comput Biol Med. 2022 Jul;146:105565 [PMID: 35594683]
  84. Am Heart J. 2017 May;187:1-9 [PMID: 28454792]
  85. Diabetes Care. 2009 Jul;32(7):1224-30 [PMID: 19289857]
  86. Iran J Public Health. 2023 Aug;52(8):1600-1612 [PMID: 37744533]
  87. JRSM Cardiovasc Dis. 2017 Jan 01;6:2048004016687211 [PMID: 28286646]
  88. Cureus. 2024 Apr 8;16(4):e57803 [PMID: 38721226]
  89. Curr Obes Rep. 2020 Jun;9(2):109-120 [PMID: 32301039]
  90. Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1538-43 [PMID: 25908765]
  91. BMJ. 2024 Jun 26;385:e078523 [PMID: 38925788]
  92. Front Pharmacol. 2020 Jun 30;11:967 [PMID: 32694999]
  93. Eur J Cardiovasc Prev Rehabil. 2010 May;17 Suppl 1:S25-31 [PMID: 20489417]
  94. Nat Rev Cardiol. 2022 Feb;19(2):133-143 [PMID: 34497402]
  95. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021 [PMID: 33309175]
  96. Cardiovasc Diabetol. 2023 Nov 20;22(1):319 [PMID: 37985992]
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0GLP-1agonistscardiovascularresearchanalysisbibliometricpeptide-1landscapediseasesclinicalfuturepublicationsglucagon-likebeyondglycemiccontroldiabetesCVDsinformingpracticeguidingendeavorstrendsfieldevolvingrolehealthUniversitytrendfocusBackground:recentyearsgarneredincreasingattentionpotentialbenefitspatientsUnderstandingsurroundingcrucialaimedcomprehensivelyassessscholarlyoutputsheddinglightagonists'Methods:concerninggatheredWebScienceCoreCollectionvisualizationscreatedutilizingExcel2019CiteSpaceVOSviewersoftwareResultsConclusion:UsingvisualmethodshotspotsregardingpinpointedAdditionallythrivinginterestwithinmedicineobservednotablesurge2016onwardsrevealedUnitedStatesChinaleadingcontributorsaccounting50%totalCopenhagenTorontoemergedprolificinstitutionsCo-citationhighlightedinfluentiallandmarktrialsLEADERELIXAEXSCELKeywordidentifiedemergencenewertirzepatidesemaglutidewellgrowingtopicslike'healthyobesity'chronickidneydiseasefindingssuggestexpandingtherapeuticapplicationsOverallprovidedinsightscurrentstatedirectionsimpactGlucagon-likediseases:inception2023mellitus

Similar Articles

Cited By